Duarte, CANCT06048250Now EnrollingIRB Ready

Multiple Myeloma Clinical Trial in Duarte, CA

Access cutting-edge multiple myeloma treatment through this phase 1 clinical trial at a research site in Duarte. Study-provided care at no cost to qualified participants.

Sponsored by City of Hope Medical Center

Quick Self-Assessment

See if you qualify for this Duarte location

Preparing your pre-screening questions…

Expert Care in Duarte

Access multiple myeloma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related multiple myeloma treatment provided free

Apply for This Duarte Location

Check if you qualify for this multiple myeloma clinical trial in Duarte, CA

Why Participate?

No-Cost Study Care
Local to Duarte
Convenient for CA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

1Submit this form
2Phone screening
3Visit Duarte site if eligible
4Begin participation

About This Multiple Myeloma Study in Duarte

This phase I trial studies the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor \[CAR\] T-cell therapy) in patients with multiple myeloma that has come back after a period of improvement (relapsed). CC-92480 works by binding to a protein called CRBN that triggers the breakdown of proteins: Ikaros and Aiolos, leading to cell death in multiple myeloma cells. Giving mezigdomide after Abecma CAR T cell therapy may extending the amount of time that the CAR T cells persist in the body in patients with relapsed multiple myeloma.

Sponsor: City of Hope Medical Center

Who Can Participate

Inclusion Criteria

Documented informed consent of the participant and/or legally authorized representative.

Assent, when appropriate, will be obtained per institutional guidelines

Age: \>= 18 years

Eastern Cooperative Oncology Group (ECOG) =\< 2

Diagnosis of multiple myeloma

Subject must have received at least 4 prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody

Receipt of commercially available idecabtagene vicleucel (Abecma) according to FDA approved US Prescribing Information. Note: Patients who received non-conforming Abecma who were originally prescribed Abecma according to the FDA approved label may be considered for inclusion per the investigators discretion. Subject must be between day 30 and day 90 post receipt of idecabtagene vicleucel

Subject must have experienced at least a stable disease in response to idecabtagene vicleucel

Fully recovered from the acute toxic effects (except alopecia) to =\< grade 1 to prior anti-cancer therapy, including idecabtagene vicleucel

Absolute neutrophil count (ANC) \>= 1,500/mm\^3 without the use of filgrastim in the previous 3 days (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)

Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met

Platelets \>= 75,000/mm\^3 without platelet transfusion in the previous 3 days. (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)

Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met

Total bilirubin =\< 1.5 X upper limit of normal (ULN) (unless has known Gilbert's disease) (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated).

Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met

Aspartate aminotransferase (AST) =\< 3 x ULN (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated).

Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met

Alanine transaminase (ALT) =\< 3 x ULN (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated).

Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met

Alkaline phosphatase =\< 5 x ULN (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)

Creatinine clearance of \>= 50 mL/min per 24 hour urine test or the Cockcroft-Gault formula (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated).

Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met

Oxygen saturation \> 92% on room air (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)

Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (To be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)

Agreement by females of childbearing potential and males to follow the guidelines of the mezigdomide (CC-92480) pregnancy prevention plan

Exclusion Criteria

Prior exposure to mezigdomide (CC-92480)

Current or planned use of other therapies other than mezigdomide (CC-92480)

Patients who are currently receiving or likely to require systemic immunosuppressive therapy. Physiologic replacement of steroids (=\< 5.0 mg/day prednisone or equivalent) is allowed

Concomitant use of CYP3A4/5 inhibitors and inducers

Concomitant use of proton pump inhibitors

Evidence of relapse as evaluated by the treating physician or study investigator

Active central nervous system involvement

Ongoing toxicities associated with cytokine release syndrome (CRS) or Immune effector cell-associated neurotoxicity syndrome (ICANS) from CAR T cell therapy

History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent

Coronavirus disease 2019 (COVID-19) positive, as assessed by a polymerase chain reaction (PCR) test or active uncontrolled infections (defined as active antibiotic use within 7 days of starting the investigational drug)

If human immunodeficiency virus (HIV) positive: CD4+ T cell count \< 200

Females only: Pregnant or breastfeeding

Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures

Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Duarte?

Yes, this clinical trial (NCT06048250) has an active research site in Duarte, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Multiple Myeloma Treatment Options in Duarte, CA

If you're searching for multiple myeloma treatment options in Duarte, CA, this clinical trial (NCT06048250) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Duarte research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all multiple myeloma clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Duarte, CA

See all multiple myeloma clinical trials recruiting in Duarte — not just this study.

Browse Multiple Myeloma Trials in Duarte →

Browse More Trials by Condition

Multiple Myeloma Trials All Conditions →

Ready to Join in Duarte?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Duarte, CA